Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE (R)) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)

B Tran, L Horvath, T Dorff, M Rettig, MP Lolkema, JP Machiels, S Rottey, K Autio, Richard Greil, N Adra, C Lemech, M Minocha, FC Cheng, H Kouros-Mehr, K Fizazi

Research output: Contribution to journalpublished Abstract (Journal)peer-review

36 Citations (Web of Science)
Original languageEnglish
Pages (from-to)S507-S507
JournalANNALS OF ONCOLOGY
Volume31
DOIs
Publication statusPublished - 2020
EventESMO Virtual Congress - ELECTR NETWORK
Duration: 19 Sept 202018 Oct 2020

Cite this